DD298348B5 - Method for controlling the quality of stored erythocytes and blood transfusions - Google Patents
Method for controlling the quality of stored erythocytes and blood transfusions Download PDFInfo
- Publication number
- DD298348B5 DD298348B5 DD33483989A DD33483989A DD298348B5 DD 298348 B5 DD298348 B5 DD 298348B5 DD 33483989 A DD33483989 A DD 33483989A DD 33483989 A DD33483989 A DD 33483989A DD 298348 B5 DD298348 B5 DD 298348B5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- transfusion
- blood
- red blood
- blood cells
- nmr spectroscopy
- Prior art date
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Zur direkten Kontrolle der Blutkonserven ist eine lokalisierte P31 -Spektroskopie im Hochfeldtomographen (B > 1,5T) am zweckmäßigsten.For direct control of the blood supply, localized P31 spectroscopy in the high field tomograph (B> 1.5T) is most appropriate.
Die P-31-NMR-Spektroskopie beeinträchtigt in keiner Weise die Lebens- und Funktionsfähigkeit der roten Blutzellen. Die Erfindung soll nachstehend an 2 Ausführungsbeispielen näher erläutert werden:P-31 NMR spectroscopy in no way affects the life and functioning of red blood cells. The invention will be explained in more detail below with reference to two exemplary embodiments:
Eine Blutkonserve wurde wie üblich aufbereitet. Die Bestimmung des 2.3-DPG-Gehaltes zur Qualitätskontrolle von Konservenblut wurde 1 bis 6 Stunden nach einer Blutabnahme sowie bis zu 14Tagen nach einer Lagerung bei 4°C durchgeführt. Zusätzlich wurden einige Blutpräparate zwischenzeitlich für mehrere Stunden auf Zimmertemperaturen aufgewärmt, um die Effekte einer Unterbrechung der Kühlkette bei der Lagerung zu ermitteln. Die 31-P-NMR-Spektren wurden mit einem PFT (Pulse Fourier Transform)-Spektrometer unter Anwendung der Quadraturdetektion bei einer Resonanzfrequenz von 162MHz ohne Protonenbreitbandkopplung aufgenommen (typische Spektrenaufnahmeparameter: Sweepbreite: 36ppm, Zeitdomäne: 16K Datenpunkte, Anzahl der Spektrenakkumulationen: 400, Wiederholzeit pro Scan: 5s für Ρί/2-Anregungsimpulse). Die zu untersuchenden Erythrozytenkonserven wurden in das Spektrometer eingebracht. Zusätzlich wurde jeder Erythrozytenkonserve noch eine Doppelkapillare beigelegt. Die äußere Kapillare enthielt D2O für den Probenlock und die innere Kapillare 85%ige H3PO4, deren NMR-Signal sowohl als Standard für die chemische Verschiebung (δ = O) als auch als Integrationsstandard für die quantitative Auswertung benutzt wurde. In Abhängigkeit vom Medium und dem pH-Wert wurden die 2 Phosphorsignale des 2.3-DPG bei δ(3Ρ) = 3,1 ± 0,5 und δ(2Ρ) = 2,9 ± 0,5 gefunden und es wurden beide Signale zur quantitativen Auswertung herangezogen, wobei die Differenz δ(3Ρ) - δ(2Ρ) zwischen 0,4 bis 0,6ppm betrug. Die Messungen wurden bei Zimmertemperatur durchgeführtA blood bank was processed as usual. The determination of the 2.3-DPG content for the quality control of preserved blood was carried out 1 to 6 hours after blood sampling and up to 14 days after storage at 4 ° C. In addition, some blood preparations have been temporarily warmed to room temperatures for several hours to determine the effects of a cold chain interruption during storage. The 31 P NMR spectra were recorded with a PFT (Pulse Fourier Transform) spectrometer using quadrature detection at a resonant frequency of 162 MHz without proton broadband coupling (typical spectral acquisition parameters: sweep width: 36ppm, time domain: 16K data points, number of spectra accumulations: 400, Repetition time per scan: 5s for Ρί / 2 excitation pulses). The erythrocyte preserves to be examined were introduced into the spectrometer. In addition, each erythrocyte preserve was given a double capillary. The outer capillary contained D2O for sample blocking and the inner capillary 85% H3PO4, whose NMR signal was used both as standard for chemical shift (δ = O) and as integration standard for quantitative evaluation. Depending on the medium and the pH value, the 2 phosphorus signals of the 2.3-DPG were found at δ (3Ρ) = 3.1 ± 0.5 and δ (2Ρ) = 2.9 ± 0.5 and both signals became quantitative difference, the difference δ (3Ρ) - δ (2Ρ) was between 0.4 to 0.6 ppm. The measurements were carried out at room temperature
Die Ergebnisse sind in Tabelle 1 dargestellt. The results are shown in Table 1.
Ausführungsbeispiel 2Embodiment 2
Zur Beurteilung des Therapieeffektes wurde Patientenblut (Blutgruppe A) nach der Transfusion von 4-6 Blutkonserven der Blutgruppe 0 in Abständen von 10min, 3,6,12,18,24,48 Stunden post transfusionem mittels Differentialagglutination aufgetrennt und die In-vivo-Regeneration von 2.3 DPG mit Hilfe der P-31-NMR-Spektroskopie ermittelt. Verwendet wurde ein Spektrometer, wie im Ausführungsbeispiel 1 beschrieben. Die aufbereiteten Blutproben wurden in NMR-Röhrchen gefüllt (Außendurchmesser 10 mm; Mindestfüllmenge: 3 ml) in die bei jeder Messung noch eine Doppelkapillare eingeführft wurde, die ebenso wie im Ausführungsbeispiel 1 beschrieben, D2O für den Probenlock und 85%ige H3PO4 als Standard und Integrationsstandard enthielt. Die Untersuchung und Auswertung erfolgte wie im Ausführungsbeispiel 1. Die Ergebnisse sind in Tabelle 2 dargestellt.To assess the therapeutic effect, patient blood (blood group A) was fractionated by differential agglutination after transfusion of 4-6 blood groups of 0 blood group at intervals of 10 min, 3,6,12,18,24,48 post-transfusion and in vivo regeneration determined by 2.3 DPG using P-31 NMR spectroscopy. A spectrometer was used as described in Example 1. The prepared blood samples were filled into NMR tubes (outer diameter 10 mm, minimum filling quantity: 3 ml) into which a double capillary was also introduced in each measurement, the same as described in Example 1, D 2 O for Probenlock and 85% H 3 PO 4 as standard and integration standard contained. The examination and evaluation were carried out as in the embodiment 1. The results are shown in Table 2.
Tabelle 1: P-31-NMR-Messungen des 2.3-DPG-Gehaltes von frischen und konservierten roten Blutzellen in Blutkonserven (Verdünnungsfaktor 2.0)Table 1: P-31 NMR measurements of 2.3-DPG content of fresh and preserved red blood cells in blood conserves (dilution factor 2.0)
* Integral (85% H3PO4) = 1 gesetzt (entspricht 0,39 mmol Glycerat^.S-Diphosphat/l)* Integral (85% H 3 PO 4 ) = 1 set (corresponds to 0.39 mmol glycerate ^ .S diphosphate / l)
Tabelle 2: P-31-NMR-Messungen zur In-vivo-Regeneration von 2.3-DPG nach Transfusion von DPG-verarmten Blutes (Verdünnungsfaktor für das Hämolysat 11.93)Table 2: P-31 NMR measurements for in vivo regeneration of 2.3-DPG after transfusion of DPG-depleted blood (dilution factor for the hemolysate 11.93)
* Integral (85%ige H3PO4) = 1 gesetzt (entspricht 0,39mmol Glycerat^.S-Diphosphat/l)* Integral (85% H 3 PO 4 ) = 1 set (corresponds to 0.39mmol glycerate ^ .S diphosphate / l)
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DD33483989A DD298348B5 (en) | 1989-11-24 | 1989-11-24 | Method for controlling the quality of stored erythocytes and blood transfusions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DD33483989A DD298348B5 (en) | 1989-11-24 | 1989-11-24 | Method for controlling the quality of stored erythocytes and blood transfusions |
Publications (1)
Publication Number | Publication Date |
---|---|
DD298348B5 true DD298348B5 (en) | 1996-01-25 |
Family
ID=5614051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DD33483989A DD298348B5 (en) | 1989-11-24 | 1989-11-24 | Method for controlling the quality of stored erythocytes and blood transfusions |
Country Status (1)
Country | Link |
---|---|
DD (1) | DD298348B5 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1597401A1 (en) * | 2003-02-17 | 2005-11-23 | Kiwi Ingenuity Limited | Preparation of red blood cells with a modified level of blood group antigen expression and their use in the quality control of blood typing reagents |
-
1989
- 1989-11-24 DD DD33483989A patent/DD298348B5/en not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1597401A1 (en) * | 2003-02-17 | 2005-11-23 | Kiwi Ingenuity Limited | Preparation of red blood cells with a modified level of blood group antigen expression and their use in the quality control of blood typing reagents |
EP1597401A4 (en) * | 2003-02-17 | 2007-08-22 | Kiwi Ingenuity Ltd | Preparation of red blood cells with a modified level of blood group antigen expression and their use in the quality control of blood typing reagents |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang | Plasma volume, cell volume, total blood volume and Fcells factor in the normal and splenectomized Sherman rat | |
Selinger et al. | Distribution volumes of [131I] albumin,[14C] sucrose, and 36Cl in sheep lung | |
Jones Jr et al. | Effects of changes in arterial O2 content on cerebral blood flow in the lamb | |
Powell et al. | Electrical properties of individual cells isolated from adult rat ventricular myocardium. | |
Kitakaze et al. | Contractile dysfunction and ATP depletion after transient calcium overload in perfused ferret hearts. | |
DE2814038C3 (en) | Material that can be labeled with a radionuclide for radioactive testing | |
DE2409598A1 (en) | GAS TRANSPORT AGENT FOR ANIMALS | |
Brugnara et al. | Effect of irradiation on red cell cation content and transport | |
CH622351A5 (en) | ||
DE1698180B2 (en) | METHOD OF MANUFACTURING A BLOOD SERUM REFERENCE STANDARD | |
DE19605246A1 (en) | Method for the calibration of gas measuring sensors for dissolved gases and method for measuring the concentration of CO2 in blood with the aid of such a calibration method | |
Robertson | The effects of experimental plethora on blood production | |
EP0265602A1 (en) | Method and device to determine hematocrit of whole blood | |
DE2333434C3 (en) | Process for carrying out serological tests according to the principle of the complement fixation reaction and ready-to-use rapid test pack for this | |
DE2850627C2 (en) | ||
DE2602997C2 (en) | Lyophilized collagen preparation and process for their manufacture | |
Rudin et al. | The action potential of spinal axons in vitro | |
Cohen et al. | Stability of Brain Intracellular Lactate and 3P-Metabolite Levels at Reduced Intracellular pH during Prolonged Hypercapnia in Rats | |
Hechtman et al. | Pulmonary entrapment of platelets during acute respiratory failure | |
Omaye et al. | Simple method for bleeding the unanaesthetized rat by tail venipuncture | |
John et al. | Quantitative changes in the canine glomerular vasculature during development: physiologic implications | |
Blaxhall | Error in haematocrit value produced by inadequate concentration of ethylenediamine tetra‐acetate | |
Trunkey et al. | The effect of septic shock on skeletal muscle action potentials in the primate | |
DD298348B5 (en) | Method for controlling the quality of stored erythocytes and blood transfusions | |
Shields | Effect of adenine on stored erythrocytes evaluated by autologous and homologous transfusions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EP | Request for examination under paragraph 12(1) filed | ||
RPV | Change in the person, the name or the address of the representative (searches according to art. 11 and 12 extension act) | ||
B5 | Patent specification, 2nd publ. accord. to extension act | ||
BAUF | Maintained restricted (sect. 12/3 extension act) | ||
RPI | Change in the person, name or address of the patentee (searches according to art. 11 and 12 extension act) | ||
ENJ | Ceased due to non-payment of renewal fee |